-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 5, NMPA's official website announced the latest batch of drug approval information, stone pharmaceutical group Oyego Pharmaceuticals' Dasatini tablets 4 imitation market application was approved and treated as a review.
Dasatini tablets for the national health insurance catalog class B varieties, Zhengda Tianqing Pharmaceutical Group in 2013 won the first imitation of the domestic, this stone drug was approved successfully won the first domestic evaluation.
Figure 1: Sales of Dasatini tablets Source: Minet China's public medical institutions terminal competition pattern is known to be dasatini tablets are chronic granulocytic leukemia special effects drugs, the original research manufacturers for Shi Guibao, in August 2011 was approved to enter the domestic market, in September 2013 Zhengda Tianqing Pharmaceutical Group was approved for market, and in December 2019 submitted a consistent evaluation application, is currently being reviewed.
Dasatini tablets entered the national health insurance catalog in 2017, maintaining an annual growth rate of more than 20%, Milnet data show that the product in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal sales of nearly 400 million yuan in 2019.
Figure 2: Dasatini tablets of enterprise competition source: Minet China's public medical institutions terminal competition pattern is currently the product market leader for Zhengda Tianqing Pharmaceutical Group, the first half of 2020 market share of up to 75.41 percent, while Shi Guibao's market share fell to 24.59 percent, this stone drug became the first over-evaluation enterprises, the future will further compress the original market or grab the share of Zhengtian Qing Pharmaceutical Group? We'll see.
sources: Milnet database, NMPA official website review data statistics as of January 5, 2021, if there are errors, please point out.
